

Supplementary Online Content

Afra TP, Razmi MT, Narang T, Dogra S, Kumar A. Topical tazarotene gel, 0.1%, as a novel treatment approach for atrophic postacne scars: a randomized active-controlled clinical trial. *JAMA Facial Plast Surg*. Published online November 15, 2018.
doi:10.1001/jamafacial.2018.1404

eTable. Correlation Between Previous Exposure to Isotretinoin and Patient Satisfaction

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Correlation Between Previous Exposure to Isotretinoin and Patient Satisfaction

Parameter		Isotretinoin exposure		p value
		Absent	Present	
PGA category at 3 rd month, microneedling group	Unsatisfied	4 (16.7%)	0 (0.0%)	0.039*
	Satisfied	17 (70.8%)	6 (50.0%)	
	Highly satisfied	3 (12.5%)	6 (50.0%)	
PGA category at 3 rd month, tazarotene group	Unsatisfied	8 (33.3%)	0 (0.0%)	0.039*
	Satisfied	13 (54.2%)	8 (66.7%)	
	Highly satisfied	3 (12.5%)	4 (33.3%)	
PGA category at 6 th month, microneedling group	Unsatisfied	2 (8.7%)	0 (0.0%)	0.061
	Satisfied	14 (60.9%)	3 (27.3%)	
	Highly satisfied	7 (30.4%)	8 (72.7%)	
PGA category at 6 th month, tazarotene group	Unsatisfied	5 (21.7%)	0 (0.0%)	0.003*
	Satisfied	17 (73.9%)	5 (45.5%)	
	Highly satisfied	1 (4.3%)	6 (54.5%)	

- *Significant p value at $p < 0.05$
- PGA, patient global assessment
- Score 0–3, unsatisfied; 4–7, satisfied; 8–10, highly satisfied.